NEWSMAX @NEWSMAX
Pfizer and its German partner BioNTech SE said their omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine. https://t.co/Jss6EbrG2y — PolitiTweet.org